Penumbra's Computer-Assisted Thrombectomy Outperforms Anticoagulation Alone

An advanced medical imaging technique reveals the intricate vascular structures affected by pulmonary embolism, informing new treatment approaches.

Apr. 14, 2026 at 12:06am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the intricate vascular structures affected by pulmonary embolism, with glowing lines and shapes against a dark background, conceptually representing the advanced medical imaging techniques informing new treatment approaches.Advanced medical imaging reveals the complex vascular structures impacted by pulmonary embolism, guiding the development of new treatment technologies like Penumbra's computer-assisted thrombectomy.Alameda Today

Penumbra, a medical device company, has announced positive 90-day results from its landmark STORM-PE randomized trial evaluating its computer-assisted vacuum thrombectomy (CAVT) technology for treating acute intermediate-high risk pulmonary embolism. The study found that CAVT plus anticoagulation achieved greater functional improvements compared to anticoagulation alone, including patients walking significantly further and experiencing no physical limitations.

Why it matters

The STORM-PE trial provides important clinical evidence supporting the use of endovascular therapy, including Penumbra's CAVT technology, as a treatment option beyond just anticoagulation for patients with acute intermediate-high risk pulmonary embolism. Improved functional outcomes and quality of life are crucial considerations for patients dealing with this serious cardiovascular condition.

The details

The STORM-PE trial evaluated 479 patients with acute intermediate-high risk pulmonary embolism. Patients treated with CAVT plus anticoagulation walked an average of 479 meters in a six-minute walk test, compared to 368 meters for the anticoagulation-only group. CAVT recipients also returned to their pre-PE functional status, while the anticoagulation-only group did not. Safety rates were comparable across both arms, with no device-related mortality or increased PE-related mortality.

  • Penumbra presented the STORM-PE findings at the Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto.
  • The STORM-PE results build on outcomes previously shared at the Vascular Interventional Advances (VIVA) 2025 Conference in November and TCT 2025 Conference.

The players

Penumbra

An Alameda, California-based medical device company that developed the Lightning Flash thrombectomy system used in the STORM-PE trial.

Dr. Robert Lookstein

Co-global principal investigator of the STORM-PE RCT and professor of radiology and surgery at Icahn School of Medicine at Mount Sinai.

Dr. Rachel Rosovsky

Co-global principal investigator of the STORM-PE randomized controlled trial, hematologist at Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School.

Dr. James F. Benenati

Penumbra's chief medical officer.

Got photos? Submit your photos here. ›

What they’re saying

“Together with the initial STORM‑PE results, which demonstrated faster reperfusion and improved right ventricular recovery, this 90 day data highlights significant patient‑centered benefits of CAVT in intermediate‑high risk PE. This pivotal trial continues to build important clinical evidence supporting the role of endovascular therapy beyond anticoagulation alone and helps inform how treatment strategies including CAVT for PE may continue to evolve in future clinical guidelines.”

— Dr. Robert Lookstein, Co-global principal investigator of the STORM-PE RCT and professor of radiology and surgery at Icahn School of Medicine at Mount Sinai

“STORM-PE continues to highlight emerging benefits of treatment beyond anticoagulation alone for patients with intermediate‑high risk PE. These functional endpoints are important because they reflect outcomes that matter to patients and directly affect their daily lives. Collectively, the STORM‑PE data suggest that PE care is evolving, and that the thoughtful adoption of endovascular treatment options has the potential to greatly improve patient outcomes and recovery.”

— Dr. Rachel Rosovsky, Co‑global principal investigator of the STORM‑PE randomized controlled trial, hematologist at Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School

“Historically, there has been limited randomized evidence describing how different treatment strategies for PE influence longer‑term recovery. In STORM‑PE, those treated with CAVT achieved significantly greater gains in objective functional measures, including 6‑minute walk distance, compared to anticoagulation alone. Data from STRIKE-PE support a similar recovery trajectory in a broader patient population. Together, these findings provide robust evidence supporting a greater role for CAVT in the treatment of acute intermediate‑high risk PE and reinforce its impact on physiological and functional outcomes.”

— Dr. James F. Benenati, Penumbra chief medical officer

What’s next

Penumbra plans to continue evaluating the long-term quality of life and functional outcomes of its CAVT technology through the ongoing STRIKE-PE real-world study, which aims to enroll up to 1,500 patients.

The takeaway

The STORM-PE trial provides compelling evidence that Penumbra's computer-assisted vacuum thrombectomy (CAVT) technology can significantly improve functional outcomes and quality of life for patients with acute intermediate-high risk pulmonary embolism, beyond what is achievable with anticoagulation alone. This represents an important advancement in the treatment of this serious cardiovascular condition.